KMT Hepatech, Inc. provides efficient and cost-effective in vivo research services utilizing our proprietary platform technology of small animal model, the KMT MouseTM.
The KMT MouseTM is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of up to 95 per cent.
We are proud to acknowledge that generated in KMT MouseTM drug therapy responses parallel those seen in humans during clinical trials.
KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.
Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:
- Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
- Safety toxicity: early assessment of potential hepatotoxicity in in vivo settings prior to first-in-human studies
- Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies
The KMT MouseTM is your essential tool for therapeutics and vaccine development.
August 07 2015
July 02 2015
KMT's CSO Dr. Tyrrell is recognized by Alberta Venture
June 01 2015
Meet KMT Hepatech at BIO International in Philadelphia, PA on June 15-18